Trial Profile
Blinded,Randomized,Multicenter phase III Study to evaluate single administration PEG-rhG-CSF100ug/kg or 6mg fixed-dose once per cycle versus daily rhG-CSFas an adjunct to chemotherapy in patients with breast cancer or NSCLC
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary) ; Filgrastim
- Indications Neutropenia
- Focus Therapeutic Use
- 06 May 2016 According to a Qilu Pharma media release, the CFDA approved PEG Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rh-G-CSF) injection on 26-Aug-2015.
- 28 Apr 2016 New trial record